Key facts
- UltraClear’s last known valuation is $134.6M (Apr 2025).
- It has raised $38.0M; the latest was PE Growth/Expansion ($23.0M) in Apr 2025.
- Notable investors include 3E Bioventures Capital, Accelmed.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for UltraClear
- ·The full record, as it builds
Funding rounds
No funding rounds for UltraClear are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About UltraClear
Developer of aesthetics and surgery technology intended to transform approaches to skin rejuvenation, body contouring, ophthalmology, and robotic surgery. The company specializes in fiber laser innovations that enable simultaneous ablative resurfacing and collagen remodeling, enabling medical professionals to deliver effective facial rejuvenation with minimal discomfort, reduced recovery time, and accelerated treatment outcomes.
- Sector
- Healthcare
- HQ
- Smithfield, RI, United States
- Founded
- 2018
- Employees
- 48
- Website
- ultraclearlaser.com/
- Ownership
- Privately Held (backing)
UltraClear doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in UltraClear shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on UltraClear in its N-PORT filings yet. We sweep new filings monthly.